Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01102569 · ClinicalTrials.gov registry record

Pancreatic Cancer Genetics

A clinical trial of Pancreatic Cancer, sponsored by Columbia University.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT01102569: Recruiting study of Pancreatic Cancer, sponsored by Columbia University.

NCT01102569 is a study of Pancreatic Cancer that is actively recruiting participants, run by Columbia University. The registered enrollment target is 100 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01102569, a study of Pancreatic Cancer, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.

Primary Outcome

The primary aim of this study is to determine the combined frequency of BRCA1 (185delAG, 5382insC) and BRCA2(6174delT) mutations in Ashkenazi Jewish pancreatic cancer patients.

Conditions Studied

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2008-01
Est. Completion 2027-12
Columbia University

958 total trials

What NCT01102569 shows while recruiting

NCT01102569 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT01102569 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01102569 about?

NCT01102569 is a clinical study titled "Pancreatic Cancer Genetics". The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary p...

What is the current status of trial NCT01102569?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2008-01. Estimated completion is 2027-12.

What conditions does trial NCT01102569 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

Who is sponsoring clinical trial NCT01102569?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01102569 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01102569's enrollment target sits among peer trials

100 106th of 278 higher than 170 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01102569, the US trial registry maintained by the National Library of Medicine. NCT01102569 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.